Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT01426802
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT01426802
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT01426802. Allocation not applicable; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- vildagliptin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01426802- Content hash
964607661efab97fe5d8e37b81743e9292f46739a1b24a82cff6d8b8589a4ae0